07:00 , Apr 3, 2014 |  BC Innovations  |  Cover Story

Critical mass in diabetes

A University of Bremen group has found a new target-serine/threonine kinase 4-that can increase b cell mass and could represent an alternative to invasive islet cell transplants in patients with diabetes. 1 Next, the team...
07:00 , Oct 28, 2013 |  BioCentury  |  Strategy

Playing in the gap

Evotec AG says its new partnership with AstraZeneca plc in kidney diseases is leveraging the biotech's ability to bridge the drug discovery gap between academia and pharma. While the company's academic deals did not generate...
07:00 , Jul 9, 2012 |  BioCentury  |  Strategy

Triple play in diabetes

The addition of Amylin Pharmaceuticals Inc. 's glucagon-like peptide 1 franchise will give partners Bristol-Myers Squibb Co. and AstraZeneca plc three modern mechanisms in their commercial diabetes portfolio and five in the pipeline - more...
07:00 , Apr 19, 2012 |  BC Innovations  |  Targets & Mechanisms

Blocking p75 NTR in diabetes

University of California, San Francisco researchers have shown that genetic deletion of the p75 neurotrophin receptor improves insulin sensitivity in diabetic mice. 1 Although targeting this receptor may offer a new way to treat insulin...